DRD
IOVA icon

Dennis R. Delaney’s Iovance Biotherapeutics IOVA Stock Holding History

Dennis R. Delaney’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$133K Hold
38,000
– – 0.05% 57
2025
Q4 		$104K Hold
38,000
– – 0.05% 48
2025
Q3 		$82.5K Hold
38,000
– – 0.04% 47
2025
Q2 		$65.4K Buy
+38,000
New +$94.6K 0.03% 48

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Dennis R. Delaney's IOVA Position: Q1 2026 in Review

Dennis R. Delaney held its Iovance Biotherapeutics (IOVA) position steady in Q1 2026 at 38,000 shares worth $133K. The position accounts for 0.05% of the portfolio, ranked #57.

Dennis R. Delaney first reported a position in IOVA in Q2 2025 and has held it in 4 quarters since. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Dennis R. Delaney held 38,000 shares of Iovance Biotherapeutics worth $133K as of Q1 2026.
  • Dennis R. Delaney left its Iovance Biotherapeutics share count unchanged in Q1 2026.
  • Iovance Biotherapeutics made up 0.05% of Dennis R. Delaney's portfolio in Q1 2026, its #57 holding.
  • Dennis R. Delaney first reported a position in Iovance Biotherapeutics in Q2 2025 and has held it in 4 quarters since.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Dennis R. Delaney's 13F filing for Q1 2026, filed 14 May 2026.